Patents by Inventor Shaobing Zhang

Shaobing Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Application of medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs
    Patent number: 11963989
    Abstract: The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.
    Type: Grant
    Filed: June 17, 2023
    Date of Patent: April 23, 2024
    Assignees: GUANGDONG XINGHAI BIOTECHNOLOGY CO., LTD., GUANGDONG XINGHAI INSTITUTE OF CELL
    Inventors: Jincheng Zeng, Shaobing Zhang
  • APPLICATION OF MEDICAL CELL CMU-PB-7 IN PREPARATION OF BLOOD LIPID-LOWERING DRUGS
    Publication number: 20230330166
    Abstract: The present invention discloses an application of a medical cell CMU-pb-7 in preparation of blood lipid-lowering drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly discovered strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of blood lipid-lowering drugs.
    Type: Application
    Filed: June 17, 2023
    Publication date: October 19, 2023
    Inventors: Jincheng Zeng, Shaobing Zhang
  • MEDICAL CELL CMU-pb-7 AND APPLICATION THEREOF IN PREPARATION OF ANTIOXIDANT DRUGS
    Publication number: 20230332099
    Abstract: The present invention discloses a medical cell CMU-pb-7 and an application thereof in preparation of antioxidant drugs, which belongs to the technical field of biology. The medical cell CMU-pb-7 disclosed by the present invention is a newly isolated and screened strain of Lactobacillus rhamnosus, having a collection number of CCTCC NO: M 2022220. The medical cell CMU-pb-7 of the present invention can enhance the antioxidant capacity of liver tissue, reduce the oxidative stress level, relieve the pathological changes of liver fat, regulate the oxidative stress level in intestinal tract, and relieve the oxidative damage to the ileum of high-fat mice. The medical cell CMU-pb-7 disclosed by the present invention has a great potential application prospect in preparation of antioxidant drugs.
    Type: Application
    Filed: June 17, 2023
    Publication date: October 19, 2023
    Inventors: Jincheng Zeng, Shaobing Zhang